(-0.39%) 5 047.25 points
(-0.19%) 37 922 points
(-0.63%) 17 460 points
(-1.45%) $80.74
(-3.01%) $1.931
(0.21%) $2 307.80
(0.47%) $26.78
(1.22%) $959.80
(0.00%) $0.937
(-0.05%) $11.09
(0.10%) $0.801
(0.01%) $93.46
@ $24.14
Utstedt: 14 feb 2024 @ 18:18
Avkastning: -27.84%
Forrige signal: feb 12 - 21:20
Forrige signal:
Avkastning: -4.60 %
Live Chart Being Loaded With Signals
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...
Stats | |
---|---|
Dagens volum | 283 615 |
Gjennomsnittsvolum | 248 839 |
Markedsverdi | 489.75M |
EPS | $0 ( 2024-04-03 ) |
Last Dividend | $0.188 ( 2023-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -11.34 |
ATR14 | $0.0280 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-08 | Kelley Erika K. | Buy | 0 | |
2024-02-20 | Minor Glenda J | Buy | 95 | Class A Common Stock |
2024-02-20 | Sutherlin Michael W | Buy | 406 | Class A Common Stock |
2024-02-20 | Shoemaker Leslie L | Buy | 43 | Class A Common Stock |
2024-02-20 | Jahnke David L | Buy | 515 | Class A Common Stock |
INSIDER POWER |
---|
-79.24 |
Last 94 transactions |
Buy: 7 552 389 | Sell: 18 343 130 |
Volum Korrelasjon
Radius Health Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
COUP | 0.943 |
APR | 0.931 |
ICON | 0.929 |
FTDR | 0.921 |
ASTL | 0.92 |
DFH | 0.918 |
CRVL | 0.917 |
KIN | 0.915 |
CLBT | 0.904 |
RMRM | 0.902 |
10 Mest negative korrelasjoner | |
---|---|
ORRF | -0.913 |
SABS | -0.913 |
MMAC | -0.908 |
LUCD | -0.908 |
VIEW | -0.905 |
AMRB | -0.89 |
SGMA | -0.887 |
LCAP | -0.885 |
LGHL | -0.884 |
TRIT | -0.883 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Radius Health Inc Korrelasjon - Valuta/Råvare
Radius Health Inc Økonomi
Annual | 2023 |
Omsetning: | $2.88B |
Bruttogevinst: | $307.71M (10.68 %) |
EPS: | $-0.920 |
FY | 2023 |
Omsetning: | $2.88B |
Bruttogevinst: | $307.71M (10.68 %) |
EPS: | $-0.920 |
FY | 2022 |
Omsetning: | $3.49B |
Bruttogevinst: | $488.07M (14.00 %) |
EPS: | $6.01 |
FY | 2021 |
Omsetning: | $229.97M |
Bruttogevinst: | $210.82M (91.67 %) |
EPS: | $-1.484 |
Financial Reports:
No articles found.
Radius Health Inc Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0.188 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.188 | 2023-04-21 |
Last Dividend | $0.188 | 2023-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-27 | |
Next Payout Date | N/A | |
# dividends | 3 | -- |
Total Paid Out | $0.563 | -- |
Avg. Dividend % Per Year | 0.60% | -- |
Score | 3.79 | -- |
Div. Sustainability Score | 8.22 | |
Div.Growth Potential Score | 5.28 | |
Div. Directional Score | 6.75 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.564 | 1.80% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00339 | 1.500 | 9.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00556 | 1.200 | 9.81 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0111 | 1.500 | -0.988 | -1.482 | [0.1 - 1] |
payoutRatioTTM | 2.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.927 | 0.800 | 5.36 | 4.29 | [1 - 3] |
quickRatioTTM | 0.883 | 0.800 | 9.51 | 7.61 | [0.8 - 2.5] |
cashRatioTTM | 0.0132 | 1.500 | -1.038 | -1.557 | [0.2 - 2] |
debtRatioTTM | 0.251 | -1.500 | 5.81 | -8.71 | [0 - 0.6] |
interestCoverageTTM | 2.18 | 1.000 | -0.303 | -0.303 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.45 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.501 | -1.500 | 7.99 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0989 | 1.000 | -1.685 | -1.685 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0117 | 1.000 | -1.766 | -1.766 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.392 | 1.000 | 8.93 | 8.93 | [0.2 - 2] |
assetTurnoverTTM | 1.639 | 0.800 | 2.41 | 1.926 | [0.5 - 2] |
Total Score | 8.22 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 47.20 | 1.000 | 5.33 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0111 | 2.50 | -0.635 | -1.482 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.095 | 2.00 | 9.64 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.31 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.55 | 2.00 | 7.82 | 10.00 | [0 - 30] |
payoutRatioTTM | 2.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.850 | 1.500 | 7.67 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0602 | 1.000 | -0.994 | 0 | [0.1 - 0.5] |
Total Score | 5.28 |
Radius Health Inc
Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.